Editas Medicine's GAAP loss for 2021 was $192.502 million, up 66% from $115.976 million in the previous year. Revenue declined 71.8% to $25.544 million from $90.732 million a year earlier.
Editas Medicine's GAAP loss for 2021 was $192.502 million, up 66% from $115.976 million in the previous year. Revenue declined 71.8% to $25.544 million from $90.732 million a year earlier. 
ir.editasmedicine.com
English (US) 